Literature DB >> 26746175

N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study.

Chiadi E Ndumele1, Kunihiro Matsushita2, Yingying Sang2, Mariana Lazo2, Sunil K Agarwal2, Vijay Nambi2, Anita Deswal2, Roger S Blumenthal2, Christie M Ballantyne2, Josef Coresh2, Elizabeth Selvin2.   

Abstract

BACKGROUND: Obesity is a risk factor for heart failure (HF) but is associated with lower N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. It is unclear whether the prognostic value and implications of NT-proBNP levels for HF risk differ across body mass index (BMI) categories. METHODS AND
RESULTS: We followed up 12 230 ARIC participants free of prior HF at baseline (visit 2, 1990-1992) with BMI ≥18.5 kg/m(2). We quantified and compared the relative and absolute risk associations of NT-proBNP with incident HF across BMI categories. There were 1861 HF events during a median 20.6 years of follow-up. Despite increased HF risk in obesity, a weak inverse association was seen between baseline BMI and NT-proBNP levels (r=-0.10). Nevertheless, higher baseline NT-proBNP was associated with increased HF risk in all BMI categories. NT-proBNP improved HF risk prediction overall, even among those with severe obesity (BMI ≥35 kg/m(2); improvement in C statistic, 0.032; 95% confidence interval, 0.011-0.053). However, given the higher HF rates among those with obesity, at each NT-proBNP level, higher BMI was associated with greater absolute HF risk. Indeed, among those with NT-proBNP of 100 to <200 pg/mL, the average 10-year HF risk was <5% among normal-weight individuals but >10% among the severely obese.
CONCLUSIONS: Despite its inverse relationship with BMI, NT-proBNP provides significant prognostic information on the risk of developing HF even among individuals with obesity. Given the higher baseline HF risk among persons with obesity, even slight elevations in NT-proBNP may have implications for increased absolute HF risk in this population.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  epidemiology; heart failure; natriuretic peptides; obesity; risk assessment

Mesh:

Substances:

Year:  2016        PMID: 26746175      PMCID: PMC4758863          DOI: 10.1161/CIRCULATIONAHA.115.017298

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  29 in total

1.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.

Authors:  Michael J Pencina; Ralph B D'Agostino
Journal:  Stat Med       Date:  2004-07-15       Impact factor: 2.373

2.  Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy.

Authors:  Daniel G Krauser; Donald M Lloyd-Jones; Claudia U Chae; Renee Cameron; Saif Anwaruddin; Aaron L Baggish; Annabel Chen; Roderick Tung; James L Januzzi
Journal:  Am Heart J       Date:  2005-04       Impact factor: 4.749

3.  Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.

Authors:  Franz Hartmann; Milton Packer; Andrew J S Coats; Michael B Fowler; Henry Krum; Paul Mohacsi; Jean L Rouleau; Michal Tendera; Alain Castaigne; Stefan D Anker; Ildiko Amann-Zalan; Silke Hoersch; Hugo A Katus
Journal:  Circulation       Date:  2004-09-20       Impact factor: 29.690

4.  N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.

Authors:  Paulo Bettencourt; Ana Azevedo; Joana Pimenta; Fernando Friões; Susana Ferreira; António Ferreira
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

5.  Impact of obesity on plasma natriuretic peptide levels.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

6.  Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching.

Authors:  P Kinnunen; O Vuolteenaho; H Ruskoaho
Journal:  Endocrinology       Date:  1993-05       Impact factor: 4.736

7.  Obesity and suppressed B-type natriuretic peptide levels in heart failure.

Authors:  Mandeep R Mehra; Patricia A Uber; Myung H Park; Robert L Scott; Hector O Ventura; Bobbett C Harris; Edward D Frohlich
Journal:  J Am Coll Cardiol       Date:  2004-05-05       Impact factor: 24.094

8.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Torbjorn Omland; Philip A Wolf; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2004-02-12       Impact factor: 91.245

9.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

10.  Obesity and the risk of heart failure.

Authors:  Satish Kenchaiah; Jane C Evans; Daniel Levy; Peter W F Wilson; Emelia J Benjamin; Martin G Larson; William B Kannel; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

View more
  34 in total

1.  Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.

Authors:  Navin Suthahar; Wouter C Meijers; Jennifer E Ho; Ron T Gansevoort; Adriaan A Voors; Peter van der Meer; Stephan J L Bakker; Stephane Heymans; Vanessa van Empel; Blanche Schroen; Pim van der Harst; Dirk J van Veldhuisen; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2018-06-01       Impact factor: 15.534

2.  Racial differences in the association of NT-proBNP with risk of incident heart failure in REGARDS.

Authors:  Nirav Patel; Mary Cushman; Orlando M Gutiérrez; George Howard; Monika M Safford; Paul Muntner; Raegan W Durant; Sumanth D Prabhu; Garima Arora; Emily B Levitan; Pankaj Arora
Journal:  JCI Insight       Date:  2019-06-04

Review 3.  SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials.

Authors:  Xiaoming Jia; Paras B Mehta; Yumei Ye; Mahboob Alam; Yochai Birnbaum; Mandeep Bajaj
Journal:  Curr Diab Rep       Date:  2018-07-11       Impact factor: 4.810

4.  High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.

Authors:  Xiaoming Jia; Wensheng Sun; Ron C Hoogeveen; Vijay Nambi; Kunihiro Matsushita; Aaron R Folsom; Gerardo Heiss; David J Couper; Scott D Solomon; Eric Boerwinkle; Amil Shah; Elizabeth Selvin; James A de Lemos; Christie M Ballantyne
Journal:  Circulation       Date:  2019-04-29       Impact factor: 29.690

5.  Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts.

Authors:  James A de Lemos; Colby R Ayers; Benjamin D Levine; Christopher R deFilippi; Thomas J Wang; W Gregory Hundley; Jarett D Berry; Stephen L Seliger; Darren K McGuire; Pamela Ouyang; Mark H Drazner; Matthew Budoff; Philip Greenland; Christie M Ballantyne; Amit Khera
Journal:  Circulation       Date:  2017-03-30       Impact factor: 29.690

Review 6.  Assessing Cardiovascular Risk and Testing in Type 2 Diabetes.

Authors:  Anum Saeed; Christie M Ballantyne
Journal:  Curr Cardiol Rep       Date:  2017-03       Impact factor: 2.931

7.  Race-based demographic, anthropometric and clinical correlates of N-terminal-pro B-type natriuretic peptide.

Authors:  Nirav Patel; Orlando M Gutiérrez; Garima Arora; George Howard; Virginia J Howard; Suzanne E Judd; Sumanth D Prabhu; Emily B Levitan; Mary Cushman; Pankaj Arora
Journal:  Int J Cardiol       Date:  2019-02-21       Impact factor: 4.164

8.  Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: ARIC Study.

Authors:  Roberta Florido; Lucia Kwak; Mariana Lazo; Vijay Nambi; Haitham M Ahmed; Sheila M Hegde; Gary Gerstenblith; Roger S Blumenthal; Christie M Ballantyne; Elizabeth Selvin; Aaron R Folsom; Josef Coresh; Chiadi E Ndumele
Journal:  Circulation       Date:  2018-01-31       Impact factor: 29.690

9.  [Dynamic changes of brain natriuretic peptide concentration and its diagnostic value for heart failure in early phase of acute myocardial infarction].

Authors:  Huidi Li; Dingcheng Xiang; Jinxia Zhang; Tianbing Duan; Feng Long; Aimin Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

10.  SES, Heart Failure, and N-terminal Pro-b-type Natriuretic Peptide: The Atherosclerosis Risk in Communities Study.

Authors:  Priya Vart; Kunihiro Matsushita; Andreea M Rawlings; Elizabeth Selvin; Deidra C Crews; Chiadi E Ndumele; Christie M Ballantyne; Gerardo Heiss; Anna Kucharska-Newton; Moyses Szklo; Josef Coresh
Journal:  Am J Prev Med       Date:  2017-12-11       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.